Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
About the Author Former Senior Writer Talon Abernathy is a former ValuePenguin Senior Writer who specialized in health insurance, Medicare and Medicaid
doi: 10.3390/biomedicines10020289 187 MarteauPSeksikPJianR
The current study was conducted to investigate the effectiveness of initiating therapy with either a GLP-1 RA or BI in real-world clinical practice in people with T2D inadequately controlled on oral antihyperglycemic drugs (OADs) by analyzing the electronic medical records (EMR) and claims data from the US Optum Humedica and UK Clinical Practice Research Datalink (CPRD) databases and to evaluate factors that might predict treatment success
(2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist Cell Metab 34(9):1234-1247
US$ 22.87
US$ 21.71
US$ 25.71
US$ 28.76
US$ 29.75
US$ 26.78
US$ 29.18
US$ 24.62
US$ 24.76
US$ 20.32
